Klacid Xl

Clarithromycin, the active ingredient in Klacid Xl, is a macrolide antibiotic presented as an oral dosage form for oral use. It treats a range of bacterial infections, including respiratory, sinus, skin and soft‑tissue infections, and is used in combination regimens for Helicobacter pylori eradication. GNH USA supplies Klacid Xl as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Clarithromycin is a macrolide antibiotic used to treat bacterial infections across several organ systems. - Community‑acquired pneumonia: eliminates the causative bacteria and improves respiratory function. - Acute bacterial sinusitis: reduces sinus inflammation by eradicating pathogenic microbes. - Skin and soft‑tissue infections: clears susceptible Staphylococcus and Streptococcus species. - Helicobacter pylori eradication (in combination therapy): contributes to bacterial clearance as part of triple‑therapy regimens. - Other susceptible bacterial infections: provides coverage for a broad spectrum of Gram‑positive and some Gram‑negative organisms.

Clarithromycin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: transient gastrointestinal upset. - Diarrhea: often mild to moderate in intensity. - Abdominal pain: cramping or discomfort in the stomach area. - Taste disturbance: altered or metallic taste perception. - Headache: mild to moderate headache episodes. - Vomiting: occasional emesis, usually self‑limiting.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - QT interval prolongation: may lead to cardiac arrhythmias. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Clostridioides difficile‑associated diarrhea: severe colitis risk. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: life‑threatening skin reactions. - Severe arrhythmias: including torsades de pointes.

Before initiating clarithromycin therapy, consider the following safety measures. - Assess renal and hepatic function: adjust therapy if impairment is present. - Monitor cardiac status: be vigilant for QT prolongation, especially in patients with cardiac risk factors. - Avoid in known hypersensitivity: discontinue if allergic reactions occur. - Use caution with concomitant CYP3A4 substrates: monitor for altered drug levels. - Pregnancy and lactation: safety data are limited; weigh benefits against potential risks. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Clarithromycin interacts with several medications; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase clarithromycin concentrations and toxicity. - QT‑prolonging agents (e.g., quinidine, sotalol): combined use raises the risk of serious cardiac arrhythmias. - Warfarin: clarithromycin can enhance anticoagulant effect, leading to elevated INR.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce clarithromycin efficacy. - Statins metabolized by CYP3A4 (e.g., simvastatin, lovastatin): monitor for signs of myopathy. - Oral contraceptives: possible reduction in contraceptive effectiveness; consider alternative methods.